ProfileProfesor Christopher Loughrey ' Co-I's Profs. Ewan CameronStuart Nicklin and Colin Berry‘Programme grant - to determine the translational importance of RUNX1 targeted therapies to prevent heart failure. ’, British Heart Foundation (BHF), £1,206,845  (2020 - 2025)

Researchers from the School of Cardiovascular & Metabolic Health have received a five-year programme grant worth over £1.2 million from the British Heart Foundation to determine the translational importance of RUNX1 targeted therapies to prevent heart failure.

They have discovered that a protein called RUNX1 is a key driver of the adverse changes in heart structure and function that lead to heart failure in patients who have had a heart attack. The programme of work led by Professor Christopher Loughrey will use a multidisciplinary approach to enhance our understanding of how adverse changes in heart structure and function lead to heart failure and provide the necessary mechanistic and preclinical data to pioneer therapeutic targeting of RUNX1 in the heart.

Professor Loughrey said: “We are immensely grateful to the British Heart Foundation for funding this work. We have brought together a world-leading, international team of clinicians and basic scientists who are entirely committed to bridging the interface between preclinical and patient data in pursuit of understanding how RUNX genes drive development of heart failure. We are excited by the prospect that treatment targeting RUNX1 has the potential one day to expedite reduction of the ever-increasing number of patients developing heart failure”.


Research members Dr Alyson Miller, Co-I Prof James Leiper, ‘Defining the role of the ADMA-DDAH1 pathway in ischaemic stroke’, British Heart Foundation (BHF), £248,780 (2020 – 2023)

This BHF project builds upon clinical data showing that elevated levels of the methylarginine ADMA and DDAH1 polymorphisms are associated with worse stroke outcomes. Through a series of integrated ex vivo and in vivo studies, it will provide the first proof-of-concept data pertaining the impact of the ADMA-DDAH1 pathway on stroke outcome. Successful outcomes from this work may lead to DDAH1 focused therapeutic approaches and provide justification of the future monitoring and stratification of at risk patients.

Dr Miller said: “James and I are immensely grateful to the BHF for funding this timely project. It will bring together the expertise of our labs with SCMH to provide much needed insight into the role of this pathway in stroke pathogenesis. We would like also thank our collaborators Dr Jozien Goense (University of Glasgow) and Dr Mairi Brittan (University of Edinburgh) for their contributions”.

First published: 3 March 2020